MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1056/nejmoa0909859

Медицинская библиотека · The New England journal of medicine · 2010

A randomized study of alglucosidase alfa in late-onset Pompe's disease.

van der Ploeg Ans T, Clemens Paula R, Corzo Deyanira, Escolar Diana M, Florence Julaine, Groeneveld Geert Jan, Herson Serge, Kishnani Priya S, Laforet Pascal, Lake Stephen L, Lange Dale J, Leshner Robert T, Mayhew Jill E, Morgan Claire, Nozaki Kenkichi, Park Dorothy J, Pestronk Alan, Rosenbloom Barry, Skrinar Alison, van Capelle Carine I, van der Beek Nadine A, Wasserstein Melissa, Zivkovic Sasa A

СтатьяМногоцентровое исследованиеРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

BACKGROUND

Pompe's disease is a metabolic myopathy caused by a deficiency of acid alpha glucosidase (GAA), an enzyme that degrades lysosomal glycogen. Late-onset Pompe's disease is characterized by progressive muscle weakness and loss of respiratory function, leading to early death. We conducted a randomized, placebo-controlled trial of alglucosidase alfa, a recombinant human GAA, for the treatment of late-onset Pompe's disease.

METHODS

Ninety patients who were 8 years of age or older, ambulatory, and free of invasive ventilation were randomly assigned to receive biweekly intravenous alglucosidase alfa (20 mg per kilogram of body weight) or placebo for 78 weeks at eight centers in the United States and Europe. The two primary end points were distance walked during a 6-minute walk test and percentage of predicted forced vital capacity (FVC).

RESULTS

At 78 weeks, the estimated mean changes from baseline in the primary end points favored alglucosidase alfa (an increase of 28.1+/-13.1 m on the 6-minute walk test and an absolute increase of 3.4+/-1.2 percentage points in FVC; P=0.03 and P=0.006, respectively). Similar proportions of patients in the two groups had adverse events, serious adverse events, and infusion-associated reactions; events that occurred only in patients who received the active study drug included anaphylactic reactions and infusion-associated reactions of urticaria, flushing, hyperhidrosis, chest discomfort, vomiting, and increased blood pressure (each of which occurred in 5 to 8% of the patients).

CONCLUSIONS

In this study population, treatment with alglucosidase alfa was associated with improved walking distance and stabilization of pulmonary function over an 18-month period. (ClinicalTrials.gov number, NCT00158600.)

Для цитирования: van der Ploeg Ans T, Clemens Paula R, Corzo Deyanira, Escolar Diana M, Florence Julaine, Groeneveld Geert Jan, Herson Serge, Kishnani Priya S, Laforet Pascal, Lake Stephen L, Lange Dale J, Leshner Robert T, Mayhew Jill E, Morgan Claire, Nozaki Kenkichi, Park Dorothy J, Pestronk Alan, Rosenbloom Barry, Skrinar Alison, van Capelle Carine I, van der Beek Nadine A, Wasserstein Melissa, Zivkovic Sasa A. A randomized study of alglucosidase alfa in late-onset Pompe's disease.. The New England journal of medicine. 2010. DOI: 10.1056/nejmoa0909859.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.